Radiotherapy with cetuximab may be superior to radiotherapy alone for patients who undergo surgery for head, neck cancer

Results from the Phase III NRG Oncology RTOG 0920 (NRG-RTOG 0920) trial assessing postoperative radiotherapy with or without concurrent cetuximab for selected patients with squamous cell cancer of the head and neck (SCCHN) showed that radiotherapy with cetuximab demonstrated superiority as measured by improved disease-free survival, a secondary endpoint.